Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease
Thieme. All rights reserved..
Post-tuberculosis lung disease (PTLD) has only recently been put in the spotlight as a medical entity. Recent data suggest that up to 50% of tuberculosis (TB) patients are left with PTLD-related impairment after completion of TB treatment. The presence of residual cavities in the lung is the largest risk factor for the development of chronic pulmonary aspergillosis (CPA) globally. Diagnosis of CPA is based on four criteria including a typical radiological pattern, evidence of Aspergillus species, exclusion of alternative diagnosis, and a chronic course of disease. In this manuscript, we provide a narrative review on CPA as a serious complication for patients with PTLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Seminars in respiratory and critical care medicine - 45(2024), 1 vom: 09. Jan., Seite 102-113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Neuböck, Matthias J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 31.01.2024 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0043-1776913 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366866559 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366866559 | ||
| 003 | DE-627 | ||
| 005 | 20240131232037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0043-1776913 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM366866559 | ||
| 035 | |a (NLM)38196060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Neuböck, Matthias J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2024 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Post-tuberculosis lung disease (PTLD) has only recently been put in the spotlight as a medical entity. Recent data suggest that up to 50% of tuberculosis (TB) patients are left with PTLD-related impairment after completion of TB treatment. The presence of residual cavities in the lung is the largest risk factor for the development of chronic pulmonary aspergillosis (CPA) globally. Diagnosis of CPA is based on four criteria including a typical radiological pattern, evidence of Aspergillus species, exclusion of alternative diagnosis, and a chronic course of disease. In this manuscript, we provide a narrative review on CPA as a serious complication for patients with PTLD | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 700 | 0 | |a for CPAnet |e verfasserin |4 aut | |
| 700 | 1 | |a Günther, Gunar |e verfasserin |4 aut | |
| 700 | 1 | |a Barac, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Davidsen, Jesper R |e verfasserin |4 aut | |
| 700 | 1 | |a Laursen, Christian B |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Ritesh |e verfasserin |4 aut | |
| 700 | 1 | |a Sehgal, Inderpaul S |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Salzer, Helmut J F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in respiratory and critical care medicine |d 1997 |g 45(2024), 1 vom: 09. Jan., Seite 102-113 |w (DE-627)NLM093752415 |x 1098-9048 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:1 |g day:09 |g month:01 |g pages:102-113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0043-1776913 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 1 |b 09 |c 01 |h 102-113 | ||